TRIAL DETAIL

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Drug:
Trial Name:
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
NCT#:
Conditions:
Gastrointestinal Stromal Tumor
Status:
Completed
Phase:
Start Date 04/01/2009
Age of Trial (yrs) 15.7
Treatment Phase:
All
Drug Category:
KIT/PDGFRA inhibitor
Strategy:
Block KIT
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
CSTI571A2403
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 800-340-6843
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country